The U.S. Food and Drug Administration declined to consider Moderna’s application for a new mRNA based flu vaccine, issuing a refusal to file that could delay a product designed to better protect older adults.

The decision centers on the trial’s choice of comparator and the FDA’s assessment that the study did not meet the standard of adequate and well controlled evidence.

Moderna chief executive Stéphane Bancel pushed back, saying the FDA's decision did not "identify any safety or efficacy concerns with our product." He added that the decision "does not further our shared goal of enhancing America’s leadership in developing innovative medicines."

"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting," Bancel said in a statement.

Here's What They're Not Telling You About Your Retirement

"We look forward to engaging with CBER to understand the path forward as quickly as possible so that America's seniors, and those with underlying conditions, continue to have access to American-made innovations."

The FDA said the comparator did not reflect the 'best-available standard of care' in its assessment. Moderna rejected that characterization, arguing that the prior guidance from the agency allowed a standard-dose comparator and that the higher dose was recommended only for those over 65.

Moderna said the FDA 'did not raise any objections or clinical hold comments about the adequacy of the Phase 3 trial after the submission of the protocol in April 2024 or at any time before the initiation of the study in September 2024.'

In August 2025, following completion of the Phase 3 efficacy trial, Moderna said it held a pre-submission meeting with CBER, which requested that supportive analyses on the comparator be included in the submission and indicated the data would be a 'significant issue during review of your BLA.'

This Could Be the Most Important Video Gun Owners Watch All Year

Moderna said it provided the additional analyses requested by CBER in its submission, noting that 'at no time in the pre-submission written feedback or meeting did CBER indicate that it would refuse to review the file.'

The company also said it had sought a Type A meeting with CBER to understand the basis for the RTF letter, while regulatory reviews are continuing in the European Union, Canada and Australia.

The episode unfolds amid broader regulatory scrutiny of mRNA vaccines and public commentary about safety and policy that has become a political issue in the current climate.

Supporters of the free market and limited government argue that a robust review process should not unduly delay innovation, and that Americans deserve access to homegrown biotechnologies.

Meanwhile the FDA continues reviews in other jurisdictions, including the European Union, Canada and Australia, signaling that this is far from a closed case.

The central takeaway is that regulatory rigor must balance patient safety with the urgency of medical progress, and the path forward will depend on clear standards and a willingness to resolve disagreements through principled, transparent review.